Efficacy and safety of camrelizumab plus docetaxel and carboplatin as neoadjuvant therapy for stage II-III triple-negative breast cancer: the HELEN-Trio 011 randomized clinical trial.
An anthracycline-free immunotherapy combination shows promise for triple-negative breast cancer, offering an alternative approach to current treatment standards.
This phase iii clinical trial examined Efficacy and safety of camrelizumab plus docetaxel and carboplatin as neoadjuvant therapy for stage II-III triple-negative breast cancer: the HELEN-Trio 011 randomized clinical trial. The PubMed abstract reports that This regimen represents a promising anthracycline-free strategy that warrants comparison with current standard chemoimmunotherapy.
What the study was
- Study design
- Phase III clinical trial
- Population
- PATIENTS AND METHODS: We performed a multicenter, randomized, open-label, phase 3 trial at 14 hospitals in C
- Sample size
- 369
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Annals of oncology : official journal of the European Society for Medical Oncology
Why it surfaced
Score 7/10 reflects phase iii clinical trial evidence with abstract only access; genuine match to Novel therapeutics: immunotherapy, CAR-T, targeted therapy.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.